Three targeted inhibitors offer new strategies for HR-positive, HER2-negative breast cancer with PIK3CA mutations.
Avani Yenamandra, PharmD, BCOP
Advertisement
Articles by Avani Yenamandra, PharmD, BCOP
BRAF V600E inhibitors show improved outcomes in relapsed/refractory hairy cell leukemia.
Second-line and later treatment options for small cell lung cancer are limited.
These combination therapies have demonstrated longer PFS with a tolerable AE profile.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
Modern Therapies Challenge Radiation’s Role in Early Breast Cancer Survival
3
FDA Grants Orphan Drug Status to Immunotherapy for Acute Myeloid Leukemia Treatment
4
Gedatolisib Triplet Shows Significant PFS Benefit in HR+/HER2– Breast Cancer
5
